Global Breast Cancer Liquid Biopsy Market Size & Outlook
Global breast cancer liquid biopsy market, 2018-2030 (US$M)
Related Markets
Global breast cancer liquid biopsy market highlights
- The global breast cancer liquid biopsy market generated a revenue of USD 277.0 million in 2021 and is expected to reach USD 1,743.1 million by 2030.
- The market is expected to grow at a CAGR (2022 - 2030) of 22.7% by 2030.
- In terms of segment, circulating cell-free dna (cfdna) accounted for a revenue of USD 155.4 million in 2021.
- Circulating Tumor Cells (CTCs) is the most lucrative biomarkers segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2021.
- Country-wise, Saudi Arabia is expected to register the highest CAGR from 2022 to 2030.
Global data book summary
| Market revenue in 2021 | USD 277.0 million |
| Market revenue in 2030 | USD 1,743.1 million |
| Growth rate | 22.7% (CAGR from 2021 to 2030) |
| Largest segment | Circulating cell-free dna (cfdna) |
| Fastest growing segment | Circulating Tumor Cells (CTCs) |
| Historical data covered | 2018 - 2020 |
| Base year for estimation | 2021 |
| Forecast period covered | 2022 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Circulating Tumor Cells (CTCs), Circulating Cell-free DNA (cfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers |
Other key industry trends
- In terms of revenue, the North America accounted for 42.8% of the global breast cancer liquid biopsy market in 2021.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Saudi Arabia is the fastest growing regional market and is projected to reach USD 14.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Cancer Liquid Biopsy Market Scope
Breast Cancer Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global breast cancer liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to breast cancer liquid biopsy market will help companies and investors design strategic landscapes.
Circulating cell-free dna (cfdna) was the largest segment with a revenue share of 56.1% in 2021. Horizon Databook has segmented the Global breast cancer liquid biopsy market based on circulating tumor cells (ctcs), circulating cell-free dna (cfdna), extracellular vesicles (evs), other circulating biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Breast Cancer Liquid Biopsy Biomarkers Outlook (Revenue, USD Million, 2018-2030)
- Circulating Tumor Cells (CTCs)
- Circulating Cell-free DNA (cfDNA)
- Extracellular Vesicles (EVs)
- Other Circulating Biomarkers
- Global Breast Cancer Liquid Biopsy Application Outlook (Revenue, USD Million, 2018-2030)
- Early Detection/Screening
- Diagnosis
- Treatment Selection
- Monitoring
Reasons to subscribe to Global breast cancer liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global breast cancer liquid biopsy market databook
-
Our clientele includes a mix of breast cancer liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global breast cancer liquid biopsy market, including forecasts for subscribers. This global databook contains high-level insights into Global breast cancer liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global breast cancer liquid biopsy market report size, by regions, 2018-2030 (US$M)
Top 10 countries: Breast cancer liquid biopsy market report size, 2021 (US$M)
Global breast cancer liquid biopsy market report share, by biomarkers, 2021 & 2030 (%, US$M)
Breast cancer liquid biopsy market: Opportunity assessment by country
Global breast cancer liquid biopsy market, by region, 2021 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
